This site is intended only for healthcare professionals resident in the Republic of Ireland
Menu
Close
Menu
Close
XELJANZ should only be used if no suitable treatment alternatives are available in patients:
-65 years of age and older;
-patients with history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long-time smokers);
-patients with malignancy risk factors (e.g. current malignancy or history of malignancy)
Considering the increased risk of serious infections, myocardial infarction, malignancies and all cause mortality with XELJANZ in patients 65 years of age and older, XELJANZ should only be used in these patients if no suitable treatment alternatives are available (see further details in section 4.4 and section 5.1 of the XELJANZ Summary of Product Characteristics).
Please refer to the XELJANZ Summary of Product Characteristics for full prescribing information
BMI=body mass index; IL-1R=interleukin-1 receptor; IL-6R=interleukin-6 receptor; RA=rheumatoid arthritis; TNF=tumor necrosis factor.
Learn more about the XELJANZ safety profile, supported by up to 9.5 years of long-term data
Want to learn more about efficacy in RA?
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
I accept and agree to the terms of use.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023